Physician

Rupesh J Parikh, MD

According to 2025 Medicare claims, Rupesh Parikh, MD (NPI: 1245249689) practices hematology/oncology in the Las Vegas-Henderson-North Las Vegas, NV market, with the plurality of this provider's patient population coming from Clark, NV. This provider's primary affiliated billing organization is ALLISON CURTIS KINGSLEY MEOZ MICHAEL & SANCHEZ PC (NPI: 1598770471; TIN: 88-0350180) and primary practice location at 89052-3908.

Parikh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 946 traditional Medicare patients, billed 408,359 HCPCS/CPT codes, and received $6,281,889 in Medicare payments. The top billing code was 82607 (Cyanocobalamin (vitamin b-12) level). Part D data shows 4,345 prescription claims across 535 beneficiaries totaling $5,144,347 in drug costs, led by Xtandi (Enzalutamide). DME data shows 54 claims. Open Payments data shows 217 records totaling $25,441. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $4,207,801 to $6,281,889. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,603,298 to $5,144,347. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $9,658 and ending at $1,269.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,137	473,644	$4,207,801
2016	1,127	530,485	$4,789,963
2017	1,182	444,745	$5,356,076
2018	1,115	368,959	$4,428,693
2019	1,084	304,031	$3,608,714
2020	1,126	485,828	$5,526,281
2021	946	371,360	$4,541,456
2022	971	383,406	$5,204,593
2023	988	439,254	$5,895,119
2024	946	408,359	$6,281,889

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	387	2,974	$1,603,298
2016	412	3,100	$1,961,526
2017	411	3,195	$1,717,202
2018	424	2,893	$2,457,509
2019	406	3,088	$2,763,911
2020	452	4,027	$2,758,418
2021	463	4,125	$3,525,952
2022	486	4,006	$3,438,517
2023	509	4,304	$4,078,952
2024	535	4,345	$5,144,347

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	143	$13,716
2016	N/R	287	$50,827
2017	N/R	133	$8,027
2018	N/R	100	$7,225
2019	N/R	60	$5,181
2020	N/R	101	$10,592
2021	N/R	12	$662
2022	N/R	11	$1,430
2023	N/R	22	$829
2024	N/R	54	$11,336

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
82607	Cyanocobalamin (vitamin b-12) level	490	721	$15
80053	Blood test, comprehensive group of blood chemicals	618	1,866	$10
36415	Insertion of needle into vein for collection of blood sample	651	2,162	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	658	2,369	$8
83615	Lactate dehydrogenase (enzyme) level	616	1,888	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	54	1,620	$733,731
Jakafi	Ruxolitinib Phosphate	36	1,080	$648,717
Pomalyst	Pomalidomide	18	504	$468,075
Revlimid	Lenalidomide	16	448	$375,861
Cabometyx	Cabozantinib S-Malate	15	450	$374,672

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
B4185	Parenteral nutrition solution, not otherwise specified, 10 grams lipids	N	N/R	18	$6,687
B4224	Parenteral nutrition administration kit, per day	N	N/R	18	$3,522
B4220	Parenteral nutrition supply kit; premix, per day	N	N/R	18	$1,127

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	210	$10,234	BeiGene USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	7	$15,207	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rupesh J. Parikh, MD?

Tedicare shows public-source Medicare data for Rupesh J. Parikh, MD (NPI 1245249689), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rupesh J. Parikh, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Rupesh J. Parikh, MD?

Rupesh J. Parikh, MD is linked to ALLISON CURTIS KINGSLEY MEOZ MICHAEL & SANCHEZ PC (billing NPI 1598770471) in the available physician profile data.

Does Rupesh J. Parikh, MD have Open Payments data?

Rupesh J. Parikh, MD has 217 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.